Recent Trends in Diagnosis and Management of Cholangiocarcinoma

An Essay
Submitted for Partial Fulfillment of Master Degree
of General Surgery

Presented By
Mario Elia Zarif Metry
M.B.B.CH

Under Supervision of **Professor/ Ashraf Farouk Abadeer**

Professor of General Surgery Faculty of Medicine Ain shams University

Doctor/ Mohamed Mahfouoz M. Omar

Lecturer of General Surgery Faculty of Medicine Ain shams University

Faculty of Medicine Ain Shams University 2011

الوسائل الحديثه في تشخيص و علاج سرطان القنوات المراريه

رسالــــة توطئه للحصول علي درجه الماجستير في الجراحة العامة

> مقدمه من الطبيب ماريو ايليا ظريف متري بكالوريوس الطب و الجراحه

تحت اشراف الاستاذ الدكتور / أشرف فاروق ابادير أستاذ الجراحه العامه كليه الطب جامعه عين شمس

دكتور /محمد محفوظ محمد عمر مدرس الجراحه العامه كليه الطب عين شمس

کلیه الطب جامعه عین شمس ۲۰۱۱

Summary

Perihilar cholangiocarcinoma includes extrahepatic and intrahepatic cholangiocarcinomas that involve the hepatic confluence of the bile duct. Although this intractable disease used to be difficult to resect as a result of complex anatomy of the hepatic hilum, diagnostic and surgical strategy has changed drastically over the past two decades. Hepatobiliary resection based on precise preoperative diagnosis of tumor extent has become a standard procedure to obtain curative resection. Despite the advance of preoperative diagnostic techniques, perihilar cholangiocarcinoma is typically diagnosed in an advanced stage at initial presentation. As only surgical resection can offer the superior survival probability, combined portal vein and liver resection and/or hepatopancreatoduodenectomy are aggressively performed at leading centers.

Most patients appear with obstructive jaundice. Even in patients without jaundice, serum alkaline phosphatase and/or g-glutamyltranspeptidase are usually elevated. Those symptoms result from bile congestion due to biliary stricture of the hepatic confluence involved by advanced cholangiocarcinoma. Ultrasonography is performed in those patients and reveals dilated intrahepatic bile ducts, the normal or atrophic gallbladder and sometimes a tumor

List of Contents

Title Page		
•	Introduction	. 1
•	Aim of the Work	.4
•	Review of Literature:	
	o Surgical Anatomy	. 5
	o Pathopysiology	19
	o Diagnosis	37
	o Treatment:-	
	(a) Surgical	63
	(b) Adjuvant	94
	(c) Palliation	98
•	Summary	.119
•	References	. 123
•	Arabic Summary	

List of Figures

Fig	No Subjects Page
1.	The gall-bladder and its duct system. (The anterior wall of the second part of the duodenum has been removed)
2.	Diagram showing the segmental anatomy of the liver 10
3.	The arterial supply of gallbladder and calot's triangle 14
4.	The Bismuth-Corlette classification of biliary stricture 30
5.	63-year-old man with hilar cholangiocarcinoma (imaging)
6.	58-year-old man with hilar cholangiocarcinoma (imaging)
7.	55-year-old man with hilar cholangiocarcinoma (imaging)
8.	60-year-old woman with hilar cholangiocarcinoma (imaging)
9.	67-year-old man with hilar cholangiocarcinoma, Bismuth-Corlette type 3a (imaging)47
10.	67-year-old man with Klatskin's tumor, type 3a (imaging)

11.	Modified T categorization in American Joint Committee on Cancer system proposed by Memorial
	Sloan–Kettering group50
12.	62-year-old woman with hilar cholangiocarcinoma (imaging)
13.	64-year-old woman with Klatskin's tumor (imaging) 52
14.	55-year-old man with hilar cholangiocarcinoma, Bismuth-Corlette type 4 (imaging)53
15.	54-year-old man with Klatskin's tumor, type 4 (imaging)
16.	67-year-old man with Klatskin's tumor (imaging)56
17.	61-year-old man with Bismuth-Corlette type 4 cholangiocarcinoma (imaging)57
18.	63-year-old man with Bismuth-Corlette type 4 cholangiocarcinoma (imaging)
19.	Specimen after extended right hepatic resection preserving parts of segment 4 for a hilar cholangiocarcinoma
20.	Intraoperative situation during an extended right hepatic resection with principle portal vein resection 83
21.	Technique for anastomosis between left hepatic duct and Roux-en-Y jejoinal limb86
22.	Self expandable metallic stent as seen from inside 100

23.	Representative fluoroscopic images of cholangio-
	carcinoma Bismuth types taken during endoscopic
	retrograde cholangiopancreaticography (ERCP) 104
24.	Correlation between magnetic resonance
	cholangiopancreaticography (MRCP) and endoscopic
	retrograde cholangiopancreaticography (ERCP) in
	hilar cholangiocarcinoma106
25.	Catheter with premounted iridium-192 seeds
	deployed within a plastic stent across a malignant
	biliarystricture

List of Tables

Tab. No	Subjects Page
1. Risk factors for cholangiocarcinoma	21
2. AJCC staging system for cholangiocarcinom	na32
3. Symptoms of cholangiocarcinoma	38
4. Criteria of irresectability of HCC	66
5. Advantages and disadvantages of resect transplantation for hilar cholangiocarcinor	

List of abbreviations

- **5FU** : 5-flurouracil

- **AJCC** : American Joint Commission on Cancer

- **ALP** : Alkaline Phosphatase

- **C.sinensis** : Clonorchis Sinensis

- **CA19-9** : Cancer Antigen 19-9

- **CC** : Cholangiocarcinoma

- **CEA** : Carcinoembryionic antigen

- **CHD** : Common Hepatic Duct

- **COX-2** : Cyclo oxyenase -2

- **CT** : Computed Tomography

- **EBRT** : External beam radiotherapy

- **ECC** : Extrahepatic cholangiocarcinoma

- **ERCP** : Endoscopic Retrograde

Cholangopancreatography

- **EUS** : Endoscopic Ultrasound

- **FDG** : F-fludrodeoxyglucose

- **FNA** : Fine needle aspiratipon

- **GGT** : Gmma Glutamyltransferase

- **HBsAg** : Hepatitis B surface antigen

- **HBV** :Hepatitis B virus

- **HCC** : Hepatocellular carcinoma

- **HCV** : Hepatitis C virus

- **HHIIUS** : High intensity intraductal ultrasound

- ICC : Intrahepatic Cholangiocarcinoma

- **ILBT** : Intraluminal brachtherapy

- **IUDS** : Intraductal ultrasound

- IVC : Inferior Vena Cava

- **LDLT** : Living donor liver transplantation

- **LT** : Liver Transplantation

- **MDCT** : Multi directional computed tomography

- **MRCP** : Magnetic resonance

cholangiopancreatographygraphy

- **MRI** : Magnetic Resonance Imaging

- **MSKCC** : Memorial Sloan-Kettering Cancer Center

- **MUC5AC** : The human mucin5, subtype A,C

- **O.viverrini**: Opisthorchis viverrini

- **OCT** : Optical coherence tomography

- **PBD** : Preoperative biliary drainage

- **PDT** : Photodynamic therapy

- **PET** : Positron Emission Tomography

- **PSC** : Primary Sclerosing Cholangitis

- **PTC** : Percutaneous transhepatic cholangiography

- **PVE** : Portal vein embolisation

- **RCT** : Radiochemotherapy

- **SEMS** : Self expandable metal stent

US : Ultrasound

- **WHO** : World Health Organisation

Acknowledgment

First and foremost thanks to **ALLAH**

I have been honored and privileged to have worked under the supervision of such distinguished and eminent Professors. It has truly been a chance of a life time

I would like to express my deepest gratitude to *Professor Dr. Ashraf Farouk Abadeer*, Professor of General Surgery, Faculty of Medicine, Ain Shams University, who had patiently supervised this work and without his supervision this work could have never been established. It has been a pleasure to proceed with this research under his supervision and guidance.

This work could not express the feeling of gratitude and respect I carry to *Dr. Mohamed Mahfouoz M. Omar*, Lecturer of General Surgery, Faculty of Medicine, Ain Shams University, For his valuable assistance, sincere advice and for spending with me much of his Precious time which gave me the push and the well to give always my best throughout this work.

Introduction

Cholangiocarcinoma is an uncommon adenocarcinoma which arises from the epithelial cells of bile ducts, anywhere along intrahepatic and extrahepatic biliary tree (*Parkin et al., 2002*).

The median age of patients at diagnosis of cholangiocarcinoma is from 60–70 Years. Sex incidence is almost equal. Strong associations have been found between cholangiocarcinoma and gallstones, sclerosing cholangitis, ulcerative colitis, cystic abnormalities of the bile duct. Although gallstones have been reported in one-third of patients with bile duct cancers. A cause-and-effect relation has not been established *(Vollmer et al., 2002)*.

Over the past few decades, remarkable advances in imaging technology have been made that allow more accurate diagnosis of biliary tract diseases and better planning of surgical procedures and other interventions aimed at managing these conditions (*Taylor et al., 2006*).

Ultrasound or computed tomography scans usually detect dilated intrahepatic bile ducts. Transhepatic cholangiography or endoscopic retrograde cholangiopancreatography clearly detect the lesion and both are

indicated in most cases. Transhepatic cholangiography is of greater value, recently MRI cholangiopancreatography (MRCP) takes the upper hand as the most informative non invasive modality for diagnosis of bile duct tumors (*Phatak and Kochman, 2004*).

Operative techniques have been improved as a result of a better understanding of biliary and hepatic anatomy and physiology. Moreover, the continuing evolution of minimally invasive surgery has promoted the gradual adoption of laparoscopic approaches to these complex operations (*Bartlett et al., 2006*).

Surgical intervention is recommended for those patients who are otherwise healthy, whose disease appears to be localized, or in whom duodenal or gastric outlet obstruction is present, palliative surgery is directed towards relieving jaundice by creating a biliary-enteric anastomosis, and if a gastric or duodenal outlet obstruction is present or a likely possibility, a gastrojejunostomy should be created at the same time. Although palliative surgery is effective in achieving its goal of circumventing the obstruction, no survival advantage has been described when compared with non-operative techniques (Furmanczyk et al., 2005).

Surgical resection including major hepatic resection remains the mainstay of treatment of hilar cholangiocarcinoma. Additional evidence is needed to fully define the role of orthotopic liver transplantation *(Ito et al., 2009)*.

Complete regional lymphadenectomy is essential for curative resection of hilar cholangiocarcinoma. Three recent series demonestrate that in patients undergoing radical lymphadenectomy, regional lymph node involvement does not significantly reduce 5-year survival. (*Kitagawa et al., 2001*).

The role of radiotherapy and chemotherapy in the treatment of cholangiocarcinoma is limited. Both modalities, either applied separately or in combination, have shown some promise, but have failed to show any survival benefit (*Harder et al., 2002*).

Palliative photodynamic therapy (PDT) and subsequent stenting resulted in longer survival than stenting alone and has a similar survival time compared with incomplete R1 and R2 resection. However, these improvements in palliative treatment by PDT will not change the concept of an aggressive resectional approach (Witzigmann et al., 2006).

Aim of Work

This work aims to review the recent trends in the diagnosis & management (operative and non-operative) of cholangiocarcinoma.